GT Medical Technologies Announces Data Demonstrating Positive Local Control and Safety Outcomes with GammaTile Therapy for Large Brain Metastases

This will be the first randomized trial comparing surgery plus GammaTile Therapy against the standard of care in patients with metastatic brain tumors.

Company Presents Multicenter, Randomized Clinical Trial of GammaTile Led by MD Anderson at the Society of Neuro-Oncology 2020 Virtual Conference on Brain Metastases

Continue reading

Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing

FDA, August 15, 2020:  Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19 infection.Continue reading

Arizona Bioscience Week Celebrates Life & Science in 2020

CHANDLER, Ariz — (BUSINESS WIRE) — The Arizona Bioindustry Association (AZBio) today announced the lineup for the fifth annual  Arizona Bioscience Week including its schedule of daily online community educational programs, a 1-hour television special Celebrating Life & Science, and the White Hat Life Science Investor Conference.  All events will take place between September 14, 2020 and September 19, 2020.Continue reading

HTG Molecular Diagnostics Announces New Commercialization and Distribution Agreement for Companion Diagnostics with QIAGEN

TUCSON, Ariz., Aug. 10, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signing of a Commercialization and Distribution Agreement (Master Agreement) with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (QIAGEN).Continue reading

FDA Approves Genentech’s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older

In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA

  • Evrysdi helped infants survive without permanent ventilation and achieve the ability to sit without support, a key motor milestone not normally seen in the natural course of the disease
  • Evrysdi is the first and only medicine for SMA that can be taken at home

Continue reading